Drugs / Cytomegalovirus Specific T-Lymphocytes
Cytomegalovirus Specific T-Lymphocytes
also known as
donor derived cytomegalovirus specific T lymphocytes
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06909110 | Apr 2025 → May 2029 expected | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | Jessie L. Alexander | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04364178 | Aug 2020 → Feb 2023 | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | Jessie L. Alexander, MD | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03004261 | Nov 2016 → Dec 2021 | cytomegalovirus infection, hematologic disorder | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cytomegalovirus Specific T-Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04364178 ↗ |
| Known as | donor derived cytomegalovirus specific T lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03004261 ↗ |
| Modality | Cell therapy | “viral specific T cells” NCT04364178 ↗ |
| Route | Intravenous | “The donor derived CMV-CTL cells will be transfused into the patients' intravenous line.” NCT03004261 ↗ |